TY - JOUR
T1 - Exerting the appropriate application of methylprednisolone in acute spinal cord injury based on time course transcriptomics analysis
AU - Yang, Liang Yo
AU - Tsai, Meng Yu
AU - Juan, Shu Hui
AU - Chang, Shwu Fen
AU - Yu, Chang Tze Ricky
AU - Lin, Jung Chun
AU - Johnson, Kory R.
AU - Lim, Hendrick Gao Min
AU - Fann, Yang C.
AU - Lee, Yuan Chii Gladys
N1 - Funding Information:
Funding: This work was supported by Ministry of Science and Technology (MOST) grants (MOST 104-2221-E-038-011-MY2, Taipei Medical University TMU106-F-010, and MOST 109-2221-E-038-016 to Y.-C.G.L., and MOST 109-2927-I-039-001 and MOST 110-2622-8-039-004-TB1 to L.-Y.Y.).
Publisher Copyright:
© 2021 by the authors. Li-censee MDPI, Basel, Switzerland.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Methylprednisolone (MP) is an anti-inflammatory drug approved for the treatment of acute spinal cord injuries (SCIs). However, MP administration for SCIs has become a controversial issue while the molecular effects of MP remain unexplored to date. Therefore, delineating the benefits and side effects of MP and determining what MP cannot cure in SCIs at the molecular level are urgent issues. Here, genomic profiles of the spinal cord in rats with and without injury insults, and those with and without MP treatment, were generated at 0, 2, 4, 6, 8, 12, 24, and 48 h post-injury. A comprehensive analysis was applied to obtain three distinct classes: side effect of MP (SEMP), com-petence of MP (CPMP), and incapability of MP (ICMP). Functional analysis using these genes suggested that MP exerts its greatest effect at 8~12 h, and the CPMP was reflected in the immune re-sponse, while SEMP suggested aspects of metabolism, such as glycolysis, and ICMP was on neurological system processes in acute SCIs. For the first time, we are able to precisely reveal responsive functions of MP in SCIs at the molecular level and provide useful solutions to avoid complications of MP in SCIs before better therapeutic drugs are available.
AB - Methylprednisolone (MP) is an anti-inflammatory drug approved for the treatment of acute spinal cord injuries (SCIs). However, MP administration for SCIs has become a controversial issue while the molecular effects of MP remain unexplored to date. Therefore, delineating the benefits and side effects of MP and determining what MP cannot cure in SCIs at the molecular level are urgent issues. Here, genomic profiles of the spinal cord in rats with and without injury insults, and those with and without MP treatment, were generated at 0, 2, 4, 6, 8, 12, 24, and 48 h post-injury. A comprehensive analysis was applied to obtain three distinct classes: side effect of MP (SEMP), com-petence of MP (CPMP), and incapability of MP (ICMP). Functional analysis using these genes suggested that MP exerts its greatest effect at 8~12 h, and the CPMP was reflected in the immune re-sponse, while SEMP suggested aspects of metabolism, such as glycolysis, and ICMP was on neurological system processes in acute SCIs. For the first time, we are able to precisely reveal responsive functions of MP in SCIs at the molecular level and provide useful solutions to avoid complications of MP in SCIs before better therapeutic drugs are available.
KW - Gly-colysis
KW - Inflammation
KW - Methylprednisolone
KW - Neurological system
KW - Oxidative stress
KW - Spinal cord injury
KW - Time course transcriptomics
UR - http://www.scopus.com/inward/record.url?scp=85120313546&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120313546&partnerID=8YFLogxK
U2 - 10.3390/ijms222313024
DO - 10.3390/ijms222313024
M3 - Article
AN - SCOPUS:85120313546
SN - 1661-6596
VL - 22
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 23
M1 - 13024
ER -